Goodwill and Intangible Assets	9 Months Ended
Goodwill and Intangible Assets	Sep. 30, 2020
Goodwill And Intangible Assets Disclosure [Abstract]
Goodwill And Intangible Assets Disclosure [Text Block]	Note 14 – Goodwill and Other Intangible Assets Changes in the carrying amount of goodwill for the nine months ended September 30, 2020 were as follows: Global Specialty Americas EMEA Asia/Pacific Businesses Total Balance as of December 31, 2019 $ 216,385 $ 133,018 $ 141,727 $ 116,075 $ 607,205 Goodwill acquired — 531 — — 531 Currency translation and other adjustments (7,262) 725 10,907 38 4,408 Balance as of September 30, 2020 $ 209,123 $ 134,274 $ 152,634 $ 116,113 $ 612,144 Other adjustments in the table above include updates to the Company’s allocation of the Houghton purchase price and associated goodwill to each of the Company’s reportable segments during the first nine months of 2020, including a $ 2.6 million decrease in the Americas, a $ 1.4 million decrease in EMEA, a $ 8.0 million increase in Asia/Pacific and a $ 0.5 million increase in Global Specialty Business. Gross carrying amounts and accumulated amortization for definite-lived intangible assets as of September 30, 2020 and December 31, 2019 were as follows: Gross Carrying Accumulated Amount Amortization 2020 2019 2020 2019 Customer lists and rights to sell $ 796,163 $ 792,362 $ 85,751 $ 49,932 Trademarks, formulations and product technology 156,837 157,049 27,872 21,299 Other 6,288 6,261 5,725 5,776 Total definite -lived intangible assets $ 959,288 $ 955,672 $ 119,348 $ 77,007 The Company amortizes definite-lived intangible assets on a straight-line basis over their useful lives. The Company recorded $ 14.0 million and $ 41.7 million of amortization expense for the three and nine months ended September 30, 2020, respectively. Comparatively, the Company recorded $ 9.2 million and $ 12.8 million of amortization expense for the three and nine months ended September 30, 2019, respectively. Estimated annual aggregate amortization expense for the current year and subsequent five years is as follows: For the year ended December 31, 2020 $ 55,447 For the year ended December 31, 2021 55,830 For the year ended December 31, 2022 55,673 For the year ended December 31, 2023 55,451 For the year ended December 31, 2024 55,025 For the year ended December 31, 2025 54,354 Goodwill and intangible assets that have indefinite lives are not amortized and are required to be assessed at least annually for impairment. The Company completes its annual goodwill and indefinite-lived intangible asset impairment test during the fourth quarter of each year. The Company continuously evaluates if triggering events indicate a possible impairment in one or more of its reporting units or indefinite-lived or long-lived assets. As of March 31, 2020, the Company evaluated the initial impact of COVID-19 on the Company’s operations, and the volatility and uncertainty in the economic outlook as a result of COVID-19 to determine if they indicated it was more likely than not that the carrying value of any of the Company’s reporting units or indefinite-lived or long-lived assets was not recoverable. The Company concluded that the impact of COVID-19 did not represent a triggering event as of March 31, 2020 with regards to the Company’s reporting units or indefinite-lived and long-lived assets, except for the Company’s Houghton and Fluidcare trademark and tradename indefinite-lived intangible assets. The determination of estimated fair value of the Houghton and Fluidcare trademark and tradename indefinite-lived assets was based on a relief from royalty valuation method which requires management’s judgment and often involves the use of significant estimates and assumptions, including assumptions with respect to the weighted average cost of capital (“WACC”) as well as projected net sales. In the first quarter of 2020, as a result of the impact of COVID-19 driving a decrease in projected legacy Houghton net sales in the current year and the impact of the current year decline on projected future legacy Houghton net sales as well as an increase in the WACC assumption utilized in the quantitative impairment assessment, the Company concluded that the estimated fair values of the Houghton and Fluidcare trademark and tradename intangible assets were less than their carrying values. As a result, an impairment charge of $ 38.0 million to write down the carrying values of these intangible assets to their estimated fair values was recorded in the first quarter of 2020. The Company’s estimate of fair value and the carrying value of these Houghton and Fluidcare trademark and tradename indefinite-lived intangible assets as of September 30, 2020 was $ 204.0 million. Comparatively, these indefinite-lived intangible assets totaled $ 242.0 million as of December 31, 2019. In addition, the Company has other indefinite-lived intangible assets totaling $ 1.1 million as of both September 30, 2020 and December 31, 2019. As of September 30, 2020, the Company continued to evaluate the on-going impact of COVID-19 on the Company’s operations, and the volatility and uncertainty in the economic outlook as a result of COVID-19, to determine if this indicated it was more likely than not that the carrying value of any of the Company’s reporting units or indefinite-lived or long-lived intangible assets were not recoverable. The Company concluded that the impact of COVID-19 did not represent a triggering event as of September 30, 2020 with regards to any of the Company’s reporting units or indefinite-lived and long-lived intangible assets. While the Company concluded that the impact of COVID-19 did not represent a triggering event as of September 30, 2020 for any of its other long-lived or indefinite-lived assets or reporting units, the Company will continue to evaluate the impact of COVID-19 on the Company’s current and projected results. If the current economic conditions worsen or projections of the timeline for recovery are significantly extended, then the Company may conclude in the future that the impact from COVID-19 requires the need to perform further interim quantitative impairment tests, which could result in additional impairment charges in the future.